ClinicalTrials.gg
CompletedNCT04576949ORCA-2Updated Jan 15, 2026Results posted

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

A Phase 3 interventional study of Cytisinicline and Placebo in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Achieve Life Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Enrollment
5th of 22
810 · median 202
Started
2020
with 1 other
Phase 3
7 of 22
none open now
Registered
12th of 22
by date
Lead sponsor
10 of 22
Achieve Life Sciences

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 7 in phase 3, and was the 12th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, age ≥18 years.
  2. Current daily cigarette smokers (averaging at least 10 cigarettes per day upon completing a 7-day screening smoking diary) and who intend to quit smoking.
  3. Expired air carbon monoxide (CO) ≥10 ppm.
  4. Failed at least one previous attempt to stop smoking with or without therapeutic support.
  5. Willing to initiate study treatment on the day after randomization and set a quit date within 5-7 days of starting treatment.
  6. Willing to actively participate in the study's smoking cessation behavioral support provided throughout the study.
  7. Able to fully understand study requirements, willing to participate, and comply with dosing schedule.
  8. Sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. More than 1 study participant in same household.
  2. Previous cytisinicline treatment in a prior clinical study or any other cytisine usage.
  3. Known to cytisinicline or any of the .
  4. Positive urinary drugs of abuse screen, determined within 28 days before the first dose of cytisinicline.
  5. abnormal serum chemistry or hematology values within 28 days of randomization (ie, requiring treatment or monitoring).
  6. Clinically significant abnormalities in 12-lead (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (ie, requiring treatment or further assessment).
  7. (BMI) classification for being underweight (\<18.5 kg/m\^2) or having ≥Class 2 obesity (≥35 kg/m\^2).
  8. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
  9. Current uncontrolled hypertension (blood pressure ≥160/100 mmHg).
  10. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic.
  11. Currently having suicidal ideation or risk for suicide ("Yes" to question 4 or question 5 OR "Yes" to any suicidal behavior question on the Columbia - Suicide Severity Rating Scale [C-SSRS]).
  12. Current symptoms of moderate to severe depression (Hospital Anxiety and Depression Scale[HADS] score ≥11).
  13. Renal impairment defined as a (CrCl) \<60 mL/min (estimated with the Cockroft-Gault equation).
  14. Hepatic impairment defined as (ALT) or aspartate aminotransferase (AST) >2.0 x the (ULN).
  15. Women who are pregnant or breast-feeding.
  16. Male or female subjects of who do not agree to use acceptable methods of during the study treatment period.
  17. Participation in a clinical study with an drug in the 4 weeks prior to randomization.
  18. Treatment with other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy [NRT]) in the 4 weeks prior to randomization or planned use of these other smoking cessation medications during the study.
  19. Use within the 2 weeks prior to randomization or planned use during the study of non-cigarette and/or noncombustible nicotine products (pipe tobacco, cigars, snuff, smokeless tobacco, hookah, e-cigarettes/vaping) or marijuana smoking or vaping.
  20. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
810 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Behavioral Support

    one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks

    Drug: Placebo · Behavioral: Behavioral support

  • Experimental
    Cytisinicline + Placebo + Behavioral Support

    one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks

    Drug: Cytisinicline · Drug: Placebo · Behavioral: Behavioral support

  • Experimental
    Cytisinicline + Behavioral Support

    one cytisinicline tablet PO TID plus behavioral support for 12 weeks

    Drug: Cytisinicline · Behavioral: Behavioral support

Interventions

  • film-coated oral tablets containing 3 mg cytisinicline

    Also known as: Cytisine

  • DrugPlacebo

    film-coated oral tablets containing matched placebo

  • BehavioralBehavioral support

    Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6

    Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤10 parts per million (ppm).

    Time frame: Weeks 3 to 6

  2. Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12

    Smoking abstinence as verified by weekly expired CO measurements ≤10 ppm.

    Time frame: Weeks 9 to 12

Secondary outcomes

  1. Percentage of Participants With Continuous Smoking Abstinence From Week 6 to Week 24

    Smoking abstinence as verified by expired CO measurements ≤10 ppm. Measurements were weekly from Week 6 to Week 12 and monthly from Week 12 to Week 16.

    Time frame: Week 6 to Week 24

  2. Percentage of Participants With Continuous Smoking Abstinence From Week 12 to Week 24

    Smoking abstinence as verified by expired CO measurements ≤10 ppm. Measurements were monthly from Week 12 to Week 24.

    Time frame: Week 12 to Week 24

  3. Percentage of Participants Taking Cytisinicline Who Were Relapse-Free at Week 24

    Relapse is defined as participant reported resuming smoking or an expired CO measure ≥ 10ppm. Relapse is defined as a participant having met one of the following: not being abstinent from Weeks 3 to 6; not being abstinent at the Week 12 visit; not abstinent or not self-reported abstinent during the Week 16 to Week 24 follow-up period. (During the follow-up period (Weeks 16 - 24) up to a total of 5 cigarettes could have been smoked.)

    Time frame: Week 24

07

Results

Posted Nov 14, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral Support
Started271269270
Completed194199225
Not completed777045
Withdrew: Adverse event132
Withdrew: Withdrawal by subject412618
Withdrew: Physician decision300
Withdrew: Death010
Withdrew: Lost to follow-up293724
Withdrew: Other, not specified231
Withdrew: Other100

Outcome measures

PrimaryPercentage of Participants With Smoking Abstinence From Weeks 3 to Week 6

Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤10 parts per million (ppm).

Time frame:
Weeks 3 to 6
Reported as:
Number · percentage of participants
Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6
percentage of participantsPlacebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support
Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 64.425.3
Statistical analysis
  • Placebo + Behavioral Support vs 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support · exact computations · p = < 0.0001 (Two-sided, calculated by exact computations with clinical site as a stratifier.) · Odds ratio (or): 8.00 · 95% CI 3.94 to 16.25Stratified by site
  • Placebo + Behavioral Support vs 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support · Exact computations · p = <0.0001 (Two-sided, derived from marginal odds ratio) · Odds ratio (or): 7.30 · 95% CI 3.92 to 14.38Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support · Cochran-Mantel-Haenszel · p = <0.0001 (p-value for difference in proportions) · Marginal difference in proportions: 0.21 · 95% CI 0.16 to 0.25
PrimaryPercentage of Participants With Smoking Abstinence From Weeks 9 to Week 12

Smoking abstinence as verified by weekly expired CO measurements ≤10 ppm.

Time frame:
Weeks 9 to 12
Reported as:
Number · percentage of participants
Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12
percentage of participantsPlacebo + Behavioral Support12 Week Cytisinicline + Behavioral Support
Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 127.032.6
Statistical analysis
  • Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · exact computations · p = < 0.0001 (Two-sided, calculated by exact computations with clinical site as a stratifier.) · Odds ratio (or): 6.29 · 95% CI 3.69 to 11.57Stratified by site
  • Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · Exact computations · p = <0.0001 (Two-sided, derived from marginal odds ratio.) · Odds ratio (or): 6.41 · 95% CI 3.81 to 11.12Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · Cochran-Mantel-Haenszel · p = <0.0001 (p-value for difference in proportions) · Marginal difference in proportions: 0.26 · 95% CI 0.20 to 0.30
SecondaryPercentage of Participants With Continuous Smoking Abstinence From Week 6 to Week 24

Smoking abstinence as verified by expired CO measurements ≤10 ppm. Measurements were weekly from Week 6 to Week 12 and monthly from Week 12 to Week 16.

Time frame:
Week 6 to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Continuous Smoking Abstinence From Week 6 to Week 24
percentage of participantsPlacebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support
Percentage of Participants With Continuous Smoking Abstinence From Week 6 to Week 242.68.9
Statistical analysis
  • Placebo + Behavioral Support vs 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support · exact computations · p = 0.0016 (Two-sided, calculated by exact computations with clinical site as a stratifier.) · Odds ratio (or): 3.67 · 95% CI 1.50 to 10.24
  • Placebo + Behavioral Support vs 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support · Exact computations · p = 0.0015 (Two-sided, derived from marginal odds ratio.) · Odds ratio (or): 3.69 · 95% CI 1.61 to 9.36Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support · Cochran-Mantel-Haenszel · p = 0.0015 (p-value for difference in proportions) · Marginal difference in proportions: 0.06 · 95% CI 0.03 to 0.09
SecondaryPercentage of Participants With Continuous Smoking Abstinence From Week 12 to Week 24

Smoking abstinence as verified by expired CO measurements ≤10 ppm. Measurements were monthly from Week 12 to Week 24.

Time frame:
Week 12 to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Continuous Smoking Abstinence From Week 12 to Week 24
percentage of participantsPlacebo + Behavioral Support12 Week Cytisinicline + Behavioral Support
Percentage of Participants With Continuous Smoking Abstinence From Week 12 to Week 244.821.1
Statistical analysis
  • Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · exact computations · p = < 0.0001 (Two-sided, calculated by exact computations with clinical site as a stratifier.) · Odds ratio (or): 5.32 · 95% CI 2.81 to 11.09Stratified by site
  • Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · Exact computations · p = <0.0001 (Two-sided, derived from marginal odds ratio.) · Odds ratio (or): 5.31 · 95% CI 2.88 to 10.29Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · Cochran-Mantel-Haenszel · p = <.0001 (p-value for difference in proportions) · Marginal difference in proportions: 0.16 · 95% CI 0.11 to 0.20
SecondaryPercentage of Participants Taking Cytisinicline Who Were Relapse-Free at Week 24

Relapse is defined as participant reported resuming smoking or an expired CO measure ≥ 10ppm. Relapse is defined as a participant having met one of the following: not being abstinent from Weeks 3 to 6; not being abstinent at the Week 12 visit; not abstinent or not self-reported abstinent during the Week 16 to Week 24 follow-up period. (During the follow-up period (Weeks 16 - 24) up to a total of 5 cigarettes could have been smoked.)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Taking Cytisinicline Who Were Relapse-Free at Week 24
percentage of participants6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral Support
Percentage of Participants Taking Cytisinicline Who Were Relapse-Free at Week 2410.413.3
Statistical analysis
  • 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · exact computations · p = 0.3484 (Two-sided, calculated by exact computations with clinical site as a stratifier.) · Odds ratio (or): 1.31 · 95% CI 0.75 to 2.33Stratified by site
  • 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · Exact computations · p = 0.3514 (Two-sided, derived from marginal odds ratio.) · Odds ratio (or): 1.32 · 95% CI 0.78 to 2.26Marginal (unadjusted) odds ratio
  • 6 Week Cytisinicline + 6 Week Placebo + Behavioral Support vs 12 Week Cytisinicline + Behavioral Support · Zelen's exact test (Pr ≤ P) · p = 0.0317 (p-value for homogeneity across sites)

Adverse events

Collected over From randomization (all-cause mortality) or first dose of study drug (adverse events) through Week 24.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Behavioral Support0/270 (0%)3/270 (1.1%)98/270 (36.3%)
6 Week Cytisinicline + 6 Week Placebo + Behavioral Support1/269 (0.4%)10/269 (3.7%)114/269 (42.4%)
12 Week Cytisinicline + Behavioral Support0/270 (0%)8/270 (3%)118/270 (43.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlacebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral Support
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2702/2690/270
Angina pectorisCardiac disorders0/2701/2690/270
Hypertensive heart diseaseCardiac disorders0/2701/2690/270
Myocardial infarctionCardiac disorders0/2701/2690/270
Small intestinal obstructionGastrointestinal disorders0/2701/2690/270
Chest painGeneral disorders0/2701/2690/270
CholecystitisHepatobiliary disorders0/2701/2690/270
HypersensitivityImmune system disorders0/2701/2690/270
Tibia fractureInjury, poisoning and procedural complications0/2701/2690/270
Diabetic ketoacidosisMetabolism and nutrition disorders0/2701/2690/270
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlacebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral Support
InsomniaPsychiatric disorders13/27023/26926/270
Abnormal dreamsPsychiatric disorders8/27022/26921/270
HeadacheNervous system disorders22/27018/26921/270
NauseaGastrointestinal disorders20/27016/26915/270
ConstipationGastrointestinal disorders3/27016/26913/270
DiarrhoeaGastrointestinal disorders15/27010/26912/270
AnxietyPsychiatric disorders5/2707/26915/270
DizzinessNervous system disorders5/27012/2696/270
Dry mouthGastrointestinal disorders3/27010/2696/270
FatigueGeneral disorders4/2709/2699/270

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral SupportTotal
Mean52.0 ± 11.9652.2 ± 11.1553.3 ± 11.5552.5 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral SupportTotal
Female159148135442
Male112121135368
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral SupportTotal
Hispanic or Latino19262368
Not Hispanic or Latino252243247742
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + Behavioral Support6 Week Cytisinicline + 6 Week Placebo + Behavioral Support12 Week Cytisinicline + Behavioral SupportTotal
American Indian or Alaska Native1214
Asian1113
Native Hawaiian or Other Pacific Islander2114
Black or African American424048130
White221222216659
More than one race0000
Unknown or Not Reported43310
08

Study locations

17 sites
  • Alliance for Multispecialty Research, LLC.
    Mobile, Alabama 36608, United States
  • Arizona State University
    Phoenix, Arizona 85044, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Clinical Research Atlanta
    Atlanta, Georgia 30281, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • AMR Lexington
    Lexington, Kentucky 40509, United States
  • Alliance for Multispecialty Research, LLC
    New Orleans, Louisiana 70119, United States
  • Massachusetts General Hospital - Clinical Genetic Research Facility
    Boston, Massachusetts 02114, United States
  • Alliance for Multispecialty Research, LLC
    Kansas City, Missouri 64114, United States
  • Alliance for Multispecialty Research, LLC
    Las Vegas, Nevada 89119, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • Coastal Carolina Research Center, Inc.
    Mt. Pleasant, South Carolina 29464, United States
  • Alliance for Multispecialty Research, LLC.
    Knoxville, Tennessee 37920, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Alliance for Multispecialty Research, LLC
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Prochaska J, Rubinstein M, Perdok R, Blumenstein B, Jacobs C. Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials. Thorax. 2026 Jan 15;81(2):164-169. doi: 10.1136/thorax-2025-223880. PubMed 40962497 ↗
  • Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B, Clarke A, Cain D, Jacobs C. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023 Jul 11;330(2):152-160. doi: 10.1001/jama.2023.10042. PubMed 37432430 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Dec 2021, 14 months.

Results were first posted in Nov 2024, 2 years 10 months after primary completion. A results delay was requested in Dec 2022.

Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Oct 6, 2020
StartActual
Oct 13, 2020
Primary completionActual
Dec 23, 2021
CompletionActual
Dec 23, 2021
Results delay requested
Dec 1, 2022
Results first posted
Nov 14, 2024
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04576949
Responsible party
Sponsor
First posted
Oct 6, 2020
Start date
Oct 13, 2020
Primary completion
Dec 23, 2021
Completion
Dec 23, 2021
Results posted
Nov 14, 2024
Last update
Jan 15, 2026

Study contacts

Nancy Rigotti, MD
principal investigator · Mass General/Harvard Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion